Tag: PROMISE II

LimFlow stent provides CLTI Patients relief

LimFlow raises US$40 million in Series D financing

LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round. A press release reports that new investors Longitude...

PROMISE II US pivotal trial of device designed for “no-option” CLTI...

Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system (LimFlow SA) designed to prevent amputations in...
LimFlow stent provides CLTI Patients relief

LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology

LimFlow SA announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification for the Japanese cohort of...
LimFlow stent provides CLTI Patients relief

First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...

LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...